Apollo Hospitals Enterprise Ltd

Core hospital network operating 73+ hospitals with ~10,500 beds across India. Includes quaternary referral hospitals, greenfield expansion hospitals, and specialty institutes. FY26 revenue: ~₹16,900 Cr. EBITDA margin targeting 24–25%.

Hospitals Day-care Clinics

Omni-channel pharmacy distribution network (5,600+ stores) combined with Apollo 24/7 digital health platform (telehealth, e-pharmacy, diagnostics). Targeted revenue run-rate: ₹25,000 Cr with 7% EBITDA by FY27. Apollo 24/7 cash loss narrowing to ₹29 Cr in Q3 FY26.

Pharmacy Digital Health Apollo 24/7

Diagnostics (Apollo Diagnostics, PathLabs), specialty clinics (Apollo Cradle maternity, Apollo Spectra day-care), and telehealth. Expanding aggressively into Tier 2/3 markets. Apollo holds ~68.8% stake. Targeted for 15%+ annual top-line growth.

Diagnostics Maternity Day-care

Apollo is restructuring its pharmacy and digital health business (Apollo HealthCo + Keimed) into a separately listed entity — Apollo HealthTech Ltd. Targeting ₹25,000 Cr revenue and 7% EBITDA by FY27, a successful listing could unlock significant conglomerate discount for existing shareholders.

Trigger: NCLT approval + listing by Q4 FY27  |  Falsification: Regulatory delays or EBITDA miss

Apollo is deploying ₹7,600–8,000 Cr over 4–5 years to add 4,300+ beds across Pune, Bengaluru, Kolkata, and NCR. New beds are expected to reach EBITDA breakeven within 12–24 months of commissioning, driving a step-up in revenue from FY27.

Trigger: First 750–1,500 beds operational in FY26/27  |  Falsification: Construction delays or start-up losses

Management is actively shifting revenue toward Cardiac, Oncology, Neurosciences, Gastro, Orthopedics, and Transplants (CONGO-T) — higher-acuity procedures with superior ARPOB. Robotic surgeries and reduced Average Length of Stay (ALOS) further improve asset utilisation.

Trigger: Double-digit CONGO-T revenue growth + ARPOB expansion  |  Falsification: Payer-mix degradation

Digital platform losses have narrowed sharply — from >₹200 Cr annually to just ₹29 Cr in Q3 FY26. A pivot from cash-burn marketing to unit-level profitability (CM1/CM2 positive) is nearly complete. Expected EBITDA breakeven by Q4 FY26 / early FY27 will be a re-rating catalyst.

Trigger: EBITDA breakeven by Q4 FY26  |  Falsification: Renewed cash-burn marketing

• Apollo HealthTech listing timeline announcement
• New Hyderabad Financial District hospital ramp-up (76th hospital)
• Fertility & maternity business divestiture proceeds deployment (₹1,550 Cr)
• Apollo 24/7 EBITDA breakeven announcement
• Q4 FY26 bed additions and early occupancy data

• Government price caps on procedures / CGHS reimbursement rates
• Skilled healthcare professional shortage driving wage inflation
• Construction delays or cost overruns in 4,300-bed expansion
• Intensifying competition from NH, Max, and Manipal chains
• Cybersecurity risk on large patient health record (PHR) database
• Pharmacy concentration risk — ~42–46% purchases via Apollo Pharmacies

Apollo is deploying ₹7,600–8,000 Cr over 4–5 years in capacity expansion. CapEx runs at approximately 6% of revenue, giving a CapEx intensity broadly in line with global hospital operators. Net Debt peaks at ~₹4,500 Cr in FY27E before declining as new hospitals reach breakeven and operating cash flows scale.

Working capital runs at approximately 5–7% of revenue. Trade receivables: ₹3,485 Cr (FY26). Pharmacy inventory: ₹542 Cr. The hospital business benefits from relatively low debtor days compared to corporate receivables, while the pharmacy distribution segment manages higher inventory turns. Consolidated working capital/revenue: ~7%.

Apollo is targeting 4,300+ new beds across greenfield and brownfield projects. Key projects include Pune (new tertiary hospital), Bengaluru (expansion of Bannerghatta Road facility), Kolkata (new standalone hospital), and NCR (expansion of DRDO campus). Total capital outlay: ₹7,600–8,000 Cr over 4–5 years.

New beds typically reach EBITDA breakeven within 12–24 months of commissioning. The company's 76th hospital in Hyderabad Financial District was recently launched, adding premium quaternary capacity in one of India's highest ARPOB markets.

The company agreed to merge Apollo HealthCo (pharmacy distribution + Apollo 24/7) with Keimed to form Apollo HealthTech Ltd — a future separately listed entity targeting ₹25,000 Cr revenue and 7% EBITDA by FY27. Apollo 24/7 cash losses have declined to just ₹29 Cr per quarter (Q3 FY26), approaching breakeven.

Additionally, Apollo divested its fertility and maternity business for ~₹1,550 Cr while retaining a minority stake, redeploying capital into higher-growth diagnostics and digital health platforms.

PM-JAY (Ayushman Bharat) covers 500M+ beneficiaries. Private health insurance is growing at 18–20% annually. Higher insurance penetration directly expands Apollo's addressable paying patient base, driving volume growth without equivalent price discounting.

India's disease burden is shifting from infectious diseases to chronic conditions — cardiovascular, oncology, diabetes, neurological. These complex, high-acuity conditions align exactly with Apollo's CONGO-T specialty strategy and command significantly higher ARPOB than general medicine.

India is the 3rd largest medical tourism destination globally. Post-COVID recovery in international patients (particularly from MENA, SAARC, and Africa) adds a high-margin revenue stream for quaternary hospitals. Apollo is a preferred destination for organ transplants and cardiac surgeries.

75% of India's population lives outside Tier-1 cities with severely limited access to quality healthcare. Apollo's AHLL strategy of diagnostics and specialty clinics in smaller cities targets this underserved market through an asset-light model with high frequency of visits.

India's digital health market is projected at $10 Bn+ by 2030. Apollo 24/7 (telehealth + e-pharmacy + diagnostics) is positioned to capture this opportunity. With 40M+ registered users and a pathway to breakeven, Apollo's digital infrastructure is a significant moat.

National Medical Commission norms require significant private sector participation to bridge India's shortfall of ~6 million hospital beds. Apollo's aggressive greenfield program directly addresses this structural shortage and enjoys regulatory tailwinds from incentivised healthcare infrastructure investment.